Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
A Lucid Thirsty Thursday D&I Special
Last week’s ‘Thirsty Thursday’ session was organised by the Lucid Group D&I Committee, whose goal is to foster a culture where diversity and inclusivity are embedded and practised within all...
Connecting capabilities in healthcare communications
The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...
Connecting capabilities in healthcare communications
The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...
Lucid Group: Orange the World
Yesterday was International Day For The Elimination Of Violence Against Women. It marked the launch of the UNiTE to end the violence against women campaign, which runs for 16 days...
Connecting capabilities in healthcare communications
The account management / medical writing paradigm was the cornerstone of medical communications for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's...
Your Lucid Group Guide to us!
Check out our Lucid Story We are a global healthcare consultancy. We deliver life-transforming value through pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. People are...
Delivering outcomes-led solutions with connected capabilities
Founded in 2007, Lucid Group has grown from a small UK-based medical education agency to a global healthcare consultancy and employs over 400 people with several offices in the UK...
Data-driven healthcare communications
Data analysis is everywhere, and the role it plays in our lives is increasing exponentially. From deciding what car to purchase to what medicine will be prescribed for us, the...
Day in a #LucidLife – Meet Nick
Nick discusses his career journey with Lucid Group and describes what a typical day at Lucid looks like for him.
Professor Andy Black joins Lucid Group as non-executive Chairman
Professor Andy Black, an experienced board-level executive for the life sciences industry, has joined Lucid Group as non-executive Chairman of the Board.Professor Black, co-founder of Kinapse − an international consultancy to the life...